Bipolar disorder and comorbid alcoholism: Prevalence rate and treatment considerations

Bipolar Disorders

Volumn 8, Issue 6, 2006, Pages 677-685

  Frye, Mark A ^a,c   Salloum, Ihsan M ^b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF PITTSBURGH   (United States)

^c MAYO CLINIC   (United States)

Author keywords

Alcohol; Antipsychotic; Bipolar; Comorbidity; Mood stabilizer

Indexed keywords

ACAMPROSATE; ANTICONVULSIVE AGENT; ANTIDEPRESSANT AGENT; ATYPICAL ANTIPSYCHOTIC AGENT; BUSPIRONE; CARBAMAZEPINE; CHLORDIAZEPOXIDE; CLOZAPINE; LITHIUM; LITHIUM CARBONATE; LORAZEPAM; MOOD STABILIZER; NALTREXONE; NEUROLEPTIC AGENT; OLANZAPINE; OXAZEPAM; PHENOBARBITAL; QUETIAPINE; TIAPRIDE; TOPIRAMATE; VALPROATE SEMISODIUM; VALPROIC ACID;

ADD ON THERAPY; AGGRESSION; ALCOHOL ABUSE; ALCOHOL WITHDRAWAL; ALCOHOLISM; BIPOLAR DEPRESSION; BIPOLAR DISORDER; BIPOLAR MANIA; CLINICAL FEATURE; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; COMORBIDITY; CORRELATION ANALYSIS; DISEASE SEVERITY; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG MECHANISM; EPIDEMIOLOGICAL DATA; GENDER BIAS; HUMAN; IMPULSIVENESS; LINKAGE ANALYSIS; LIVER FUNCTION; MIXED MANIA AND DEPRESSION; MONOTHERAPY; PATIENT COMPLIANCE; PHENOMENOLOGY; PHENOTYPIC VARIATION; PREVALENCE; PRIORITY JOURNAL; PSYCHOPHARMACOTHERAPY; RAPID CYCLING BIPOLAR DISORDER; RELAPSE; REVIEW; RISK ASSESSMENT; SIDE EFFECT; SUICIDAL BEHAVIOR; SYMPTOMATOLOGY; TREATMENT PLANNING;

ALCOHOLISM; ANTIPSYCHOTIC AGENTS; BIPOLAR DISORDER; COMORBIDITY; HUMANS; PREVALENCE;

EID: 34248558680     PISSN: 13985647     EISSN: 13995618     Source Type: Journal    
DOI: 10.1111/j.1399-5618.2006.00370.x     Document Type: Review

References (63)

1. Kraepelin E. Manic-Depressive Insanity and Paranoia. Classics in Psychiatry. Salem, NH: Ayer Company, Publishers, Inc., 1921.
2. Goodwin F, Jamison KR. Manic-Depressive Illness. New York: Oxford University Press, 1990.
3. Robins LN, Price RK. Adult disorders predicted by childhood conduct problems: Results from the NIMH Epidemiologic Catchment Area project. Psychiatry 1991; 54: 116-132.
4. Quanbeck CD, Stone DC, Scott CL, McDermott BE, Altshuler LL, Frye MA. Clinical and legal correlates of inmates with bipolar disorder at time of criminal arrest. J Clin Psychiatry 2004; 65: 198-203.
5. Judd LL, Akiskal HS, Schettler PJ et al. The long-term natural history of the weekly symptomatic status of bipolar I disorder. Arch Gen Psychiatry 2002; 59: 530-537.
6. Regier DA, Farmer ME, Rae DS et al. Comorbidity of mental disorders with alcohol and other drug abuse. Results from the Epidemiologic Catchment Area (ECA) Study. JAMA 1990; 264: 2511-2518.
7. Kessler RC, Crum RM, Warner LA, Nelson CB, Schulenberg J, Anthony JC. Lifetime co-occurrence of DSM-III-R alcohol abuse and dependence with other psychiatric disorders in the National Comorbidity Survey. Arch Gen Psychiatry 1997; 54: 313-321.
8. Brady KT, Lydiard RB. Bipolar affective disorder and substance abuse. J Clin Psychopharmacol 1995; 12: 17S-22S.
9. Grant BF, Stinson FS, Dawson DA et al. Prevalence and co-occurrence of substance use disorders and independent mood and anxiety disorders: results from the National Epidemiologic Survey on Alcohol and Related Conditions. Arch Gen Psychiatry 2004; 61: 807-816.
10. Winokur G, Coryell W, Akiskal HS et al. Alcoholism in manic-depressive (bipolar) illness: Familial illness, course of illness, and the primary-secondary distinction. Am J Psychiatry 1995; 152: 365-372.
11. Winokur G, Turvey C, Akiskal H et al. Alcoholism and drug abuse in three groups-bipolar I, unipolars and their acquaintances. J Affect Disord 1998; 50: 81-89.
12. Strakowski SM, Sax KW, McElroy SL, Keck PE Jr, Hawkins JM, West SA, inventors. Course of psychiatric and substance abuse syndromes co-occurring with bipolar disorder after a first psychiatric hospitalization. J Clin Psychiatry 1998; 59: 465-471.
13. Frye MA, Altshuler LL, McElroy SL et al. Gender differences in prevalence, risk, and clinical correlates of alcoholism comorbidity in bipolar disorder. Am J Psychiatry 2003; 160: 883-889.
14. Salloum IM, Cornelius JR, Mezzich JE et al. Characterizing female bipolar alcoholic patients presenting for initial evaluation. Addict Behav 2001; 26: 341-348.
15. Salloum IM, Cornelius JR, Mezzich JE, Kirisci L. Impact of concurrent alcohol misuse on symptom presentation of acute mania at initial evaluation. Bipolar Disord 2002; 4: 418-421.
16. Feinman JA, Dunner DL. The effect of alcohol and substance abuse on the course of bipolar affective disorder. J Affect Disord 1996; 37: 43-49.
17. Sonne SC, Brady KT, Morton WA. Substance abuse and bipolar affective disorder. J Nerv Ment Dis 1994; 182: 349-352.
18. Black DW, Winokur G, Bell S, Nasrallah A, Hulbert J. Complicated mania. Comorbidity and immediate outcome in the treatment of mania. Arch Gen Psychiatry 1988; 45: 232-236.
19. Tohen M, Waternaux CM, Tsuang MT, Hunt AT. Four-year follow-up of twenty-four first-episode manic patients. J Affect Disord 1990; 19: 79-86.
20. O'Connell RA, Mayo JA, Flatow L, Cuthbertson B, O'Brien BE. Outcome of bipolar disorder on long-term treatment with lithium. Br J Psychiatry 1991; 159: 123-129.
21. Keller MB, Lavori PW, Coryell W et al. Differential outcome of pure manic, mixed/cycling, and pure depressive episodes in patients with bipolar illness. JAMA 1986; 22: 3138-3142.
22. Himmelhoch JM, Mulla D, Neil JF, Detre TP, Kupfer DJ. Incidence and significiance of mixed affective states in a bipolar population. Arch Gen Psychiatry 1976; 33: 1062-1066.
23. Aagaard J, Vestergaard P. Predictors of outcome in prophylactic lithium treatment: A 2-year prospective study. J Affect Disord 1990; 18: 259-266.
24. Nagel K, Adler LE, Bell J, Nagamoto HT, Freedman R. Lithium carbonate and mood disorder in recently detoxified alcoholics: A double-blind, placebo-controlled pilot study. Alcohol Clin Exp Res 1991; 15: 978-981.
25. Merry J, Reynolds CM, Bailey J, Coppen A. Prophylactic treatment of alcoholism by lithium carbonate. A controlled study. Lancet 1976; 1: 481-482.
26. Kline NS, Wren JC, Cooper TB, Varga E, Canal O. Evaluation of lithium therapy in chronic and periodic alcoholism. Am J Med Sci 1974; 268: 15-22.
27. Dorus W, Ostrow DG, Anton R et al. Lithium treatment of depressed and nondepressed alcoholics. JAMA 1989; 262: 1646-1652.
28. Fawcett J, Kravitz HM, McGuire M et al. Pharmacological treatments for alcoholism: Revisiting lithium and considering buspirone. Alcohol Clin Exp Res 2000; 24: 666-674.
29. Ballenger JC, Post RM. Kindling as a model for alcohol withdrawal syndromes. Br J Psychiatry 1978; 133: 1-14.
30. Brown ME, Anton RE, Malcom R, Ballenger JC. Alcohol detoxification and withdrawal seizures clinical support for a kindling hypothesis. Biol Psychiatry 1988; 23: 507-514.
31. Booth BM, Blow FC. The kindling hypothesis: Further evidence from a U.S. national study of alcoholic men. Alcohol 1993; 28: 593-598.
32. Frye MA, Altshuler LL. Selection of initial treatment for bipolar disorder, manic phase. Mod Probl Pharmacopsychiatry 1997; 25: 88-113.
33. Weisler RH, Kalali AH, Ketter TA; SPD417 Study Group. A multicenter, randomized, double-blind, placebo-controlled trial of extended release carbamazepine capsules as monotherapy for bipolar disorder patients with manic or mixed episodes. J Clin Psychiatry 2004; 65: 478-484.
34. Weisler RH, Keck PE Jr, Swann AC, Cutler AJ, Ketter TA, Kalali AH; SPD417 Study Group. Extended-release carbamazepine capsules as monotherapy for acute mania in bipolar disorder: A multi-center, randomized, double blind, placebo-controlled trial. J Clin Psychiatry 2005; 66: 659.
35. Keck PE Jr, McElroy SL, Friedman LM. Valproate and carbamazepine in the treatment of panic and posttraumatic stress disorders, withdrawal states, and behavioral dyscontrol syndromes. J Clin Psychopharmacol 1992; 12: 36S-41S.
36. Malcolm R, Ballenger JC, Sturgis ET, Anton R. Double-blind controlled trial comparing carbamazepine to oxazepam treatment of alcohol withdrawal. Am J Psychiatry 1989; 146: 617-621.
37. Malcolm R, Myrick H, Roberts J, Wang W, Anton RF, Ballenger JC. The effects of carbamazepine and lorazepam on single versus multiple previous alcohol withdrawals in an outpatient randomized trial. J Gen Intern Med 2002; 17: 349-355.
38. Mueller TI, Stout RL, Rudden S et al. A double-blind, placebo-controlled pilot study of carbamazepine for the treatment of alcohol dependence. Alcohol Clin Exp Res 1997; 21: 86-92.
39. Bjorkqvist SE, Isohanni M, Makela R, Malinen L. Ambulant treatment of alcohol withdrawal symptoms with carbamazepine: A formal multicentre double-blind comparison with placebo. Acta Psychiatr Scand 1976; 53: 333-342.
40. Hammer BA, Brady KT. Valproate treatment of alcohol withdrawal and mania. Am J Psychiatry 1996; 153: 1232.
41. Lambie D, Johnson RH, Vijayasenan ME, Whiteside EA. Sodium valproate in the treatment of the alcohol withdrawal syndrome. Aust N Z J Psychiatry 1980; 14: 213-215.
42. Rosenthal RN, Perkel C, Singh P, Anand O, Miner CR. A pilot open randomized trial of valproate and phenobarbital in the treatment of acute alcohol withdrawal. Am J Addict 1998; 7: 189-197.
43. Myrick H, Brady KT, Malcolm R. Divalproex in the treatment of alcohol withdrawal. Am J Drug Alcohol Abuse 2000; 26: 155-160.
44. Longo LP, Campbell T, Hubatch S. Divalproex sodium (Depakote) for alcohol withdrawal and relapse prevention. J Addict Dis 2002; 21: 55-64.
45. Reoux JP, Saxon AJ, Malte CA, Baer JS, Sloan KL. Divalproex sodium in alcohol withdrawal: A randomized double-blind placebo-controlled clinical trial. Alcohol Clin Exp Res 2001; 25: 1324-1329.
46. Brady KT, Myrick H, Henderson S, Coffey SF. The use of divalproex in alcohol relapse prevention: A pilot study. Drug Alcohol Depend 2002; 67: 323-330.
47. Brady KT, Sonne SC, Anton R, Ballenger JC. Valproate in the treatment of acute bipolar affective episodes complicated by substance abuse: A pilot study. J Clin Psychiatry 1995; 56: 118-121.
48. Salloum IMC Jr, Daley DC, Kirisci L, Himmelhoch J, Thase ME. Efficacy of valproate in bipolar alcoholics: A double blind, placebo-controlled study. Bipolar Disord 2003; 5 (Suppl. 1): 80.
49. Altshuler LL, Cohen L, Szuba MP, Burt VK, Gitlin M, Mintz J. Pharmacologic management of psychiatric illness during pregnancy: dilemmas and guidelines. Am J Psychiatry 1996; 154: 592-606.
50. Kushner SF, Khan A, Olson WH. Topiramate monotherapy in the management of acute mania: Results of four double-blind placebo controlled trials. Bipolar Disord 2006; 8: 15-27.
51. Moghaddam B, Bolinao ML. Glutamatergic antagonists attenuate ability of dopamine uptake blockers to increase extracellular levels of dopamine: implications for tonic influence of glutamate on dopamine release. Synapse 1994; 18: 337-342.
52. Skradski S, White HS. Topiramate blocks kainate-evoked cobalt influx into cultured neurons. Epilepsia 2000; 41 (Suppl. 1): S45-S47.
53. Rubio G, Ponce G, Jimenez-Arriero MA, Palomo T, Manzanares J, Ferre F. Effects of topiramate in the treatment of alcohol dependence. Pharmacopsychiatry 2004; 37: 37-40.
54. Johnson BA, Ait-Daoud N, Bowden CL et al. Oral topiramate for treatment of alcohol dependence: A randomised controlled trial. Lancet 2003; 361: 1677-1685.
55. Bialer M, Doose DR, Murthy B et al. Pharmacokinetic interactions of topiramate. Clin Pharmacokinet 2004; 43: 763-780.
56. Salloum IM, Cornelius JR, Chakravorthy S. Combined naltrexone valproate in bipolar alcoholics: A randomized, open-label, pilot study. Bipolar Disord 2003; 5 (Suppl. 1): 79-80.
57. Frye MA, Ketter TA, Leverich GS et al. The increasing use of polypharmacotherapy for refractory mood disorders: 22 years of study. J Clin Psychiatry 2000; 61: 9-15.
58. Shaw GK, Majumdar SK, Waller S, MacGarvie J, Dunn G. Tiapride in the long-term management of alcoholics of anxious or depressive temperament. Br J Psychiatry 1987; 150: 164-168.
59. Hutchison KE, Swift R, Rohsenow DJ, Monti PM, Davidson D, Almeida A. Olanzapine reduces urge to drink after drinking cues and a priming dose of alcohol. Psychopharmacology (Berl) 2001; 155: 27-34.
60. Brown ES, Nejtek VA, Perantie DC, Bobadilla L. Quetiapine in bipolar disorder and cocaine dependence. Bipolar Disord 2002; 4: 406-411.
61. Longoria J, Brown ES, Perantie DC, Bobadilla L, Nejtek VA. Quetiapine for alcohol use and craving in bipolar disorder. J Clin Psychopharmacol 2004; 24: 101-102.
62. Green AI, Burgess ES, Dawson R, Zimmet SV, Strous RD. Alcohol and cannabis use in schizophrenia: Effects of clozapine vs. risperidone. Schizophr Res 2003; 60: 81-85.
63. Drake RE, Xie H, McHugo GJ, Green AI. The effects of clozapine on alcohol and drug use disorders among patients with schizophrenia. Schizophr Bull 2000; 26: 441-449.